Skip to content

Dilated Cardiomyopathy 2a C2678474

Published: July 22, 2026Updated: August 20, 2026

A hereditary subtype of dilated cardiomyopathy that causes progressive weakening and enlargement of the heart's main pumping chamber. Patients may experience fatigue, shortness of breath, and fluid retention. Management includes medications and regular cardiac follow-up.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
B33.24
ICD-11
1A00.0
Body system
cardiovascular
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Chest discomfort

!

Syncope

Chest discomfort or palpitations

(cardiovascular)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Dyspnea on exertion

(cardiovascular)

Palpitations

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

ACE Inhibitors or ARBs

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are cornerstone heart failure medications that reduce cardiac workload and prevent adverse remodeling of the heart muscle.

medication
2

Disease management and monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Sodium and Fluid Restriction

Daily sodium intake limited to 2,000mg or less with careful fluid monitoring to reduce fluid retention and decrease cardiac burden.

lifestyle

Additional treatment options

Echocardiogram Surveillance

Regular cardiac imaging to assess left ventricular ejection fraction, chamber dimensions, and disease progression every 3-6 months.

monitoring

Beta-Blocker Therapy

Non-selective or cardioselective beta-blockers to reduce heart rate, decrease myocardial oxygen demand, and improve ventricular function over time.

medication

Cardiac Rehabilitation Program

Supervised exercise program designed to safely improve cardiovascular endurance while monitoring for signs of decompensation.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dilated Cardiomyopathy 2a C2678474?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dilated Cardiomyopathy 2a C2678474. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy